🇺🇸 FDA
Pipeline program

AV-101

VSG-CL 003

Phase 2 small_molecule completed

Quick answer

AV-101 for Major Depressive Disorder is a Phase 2 program (small_molecule) at Vistagen Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Vistagen Therapeutics
Indication
Major Depressive Disorder
Phase
Phase 2
Modality
small_molecule
Status
completed

Clinical trials